Theralink Technologies Inc (THER)

[LCJR]

I reached out to the company to set up an appointment to meet and talk but never got a response back from them. Curious after my email they immediately released that last PR.

I can understand if they’re in a quiet period, but it is allowed to let everyone know they’re in a quiet period instead of just ignoring folks. I didn’t care for that.

LCJR

[learningcurve2020]

Come on Faith...Show your shareholders that tenth of a penny gain!!! LOL


https://theralink.com/service/management-team/

[LCJR]

Ah, gotcha. Yep, I think that’s what’s going to happen. First the share structure changes and then the merger with uplisting request if it’s not already in the works. It will hit when everyone’s sleeping on this, but end of 4th QTR is end of December so time is running out to gather shares.


LCJR

[learningcurve2020]

They've been saying that for a while now. My point is get it done then release news.

[LCJR]

You read the filings, right? Share structure is about to be reduced.

LCJR

[learningcurve2020]

Makes zero sense to put out positive new with the current share structure. Careful green retail.

[carusso]

Nice article!

[LCJR]

$THER https://www.otcmarkets.com/stock/THER/news/story?e&id=2678926

LCJR

[LCJR]

$THER. News out:


Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board

Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute (Inova) is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova’s Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients.

The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova’s molecular tumor board’s operational workflow. Over the past year, Inova has undertaken a feasibility study to develop and implement the procedures and infrastructure necessary for proteomic analysis within the context of the Inova Schar Molecular Tumor Board. The Theralink assay provides a direct means of determining the actionability of genomic derangements identified, as well as directly measuring the activation/elevation of protein drug targets otherwise missed by genomic analysis alone. Thus, the incorporation of key phosphoprotein and protein data generated by Theralink’s RPPA technology into the Inova MTB could synergize with current genomics analysis to produce more accurate treatment selection and patient-tailored therapy regimes.

Interim results of this pan-tumor study were presented at the 2023 ASCO Conference in Chicago. Specifically, the analysis examined the feasibility of incorporating laser capture microdissection (LCM) enrichment of tumor specimens and reverse phase protein array (RPPA) analysis with next generation sequencing (NGS) into a molecular tumor board for improving selection of targeted cancer therapy. Integrated review of the RPPA and NGS data by the MTB supported a clinical recommendation change for over half of the patients overall. Further, the proteomics data from the Theralink assay provided additional treatment considerations for 59% of the patients, the outcomes for whom continue to be monitored. Moreover, the collaboration with Inova and their MTB resulted in a recent finding1 wherein the Theralink proteomics data revealed a specific mechanism of resistance and likely lack of benefit to a targeted therapy being considered by the MTB for a patient with a rare form of inflammatory myofibroblastic cancer.

Lastly, Inova and Theralink presented the results of another important study at ASCO 2023 that focused on Theralink’s unique ability to quantitatively measure HER2 abundance and activation and found that nearly 50% of pancreatic tumor actually express moderate amounts of HER2 protein, which could be missed by existing commercial HER2 assays. While HER2 expression is not routinely evaluated in clinical practice for pancreatic cancer these results may have clinical implications, especially as new classes of HER2 antibody drug conjugates are considered for patients with HER2 non amplified tumors across organ sites.

“Theralink is extremely encouraged by the work done to date at Inova Schar Cancer Institute- the interim results and clinical intelligence speak for themselves. We look forward to completing this study with Inova for our mutual goal of improving outcomes for all cancer patients”, said Faith Zaslavsky, President and Chief Executive Officer of Theralink.

Dr. Timothy Cannon, who is the Sheridan Director of the Inova Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova said, “We have tested over 100 patients with Theralink’s RPPA technology as part of this study. We are hopeful final study analysis and results will continue to underscore the importance of real-time clinical integration of functional protein drug target activation data provided by the Theralink assay with NGS in the Inova MTB for cancer patients.”

Theralink and Inova will update findings and results post study completion. Published results are anticipated in early 2024.

[gdog]

news I cant find how to copy and paste

[carusso]

Oh… Definitely

[learningcurve2020]

If it's within easy driving range I sure do. And, this isn't any old company we're talking about as it appears skeleton like.

[LCJR]

Do you go visit each company you invest or play? I think not. We rely on research.
Eye rolls.

LCJR

[learningcurve2020]

Nah. It's better to load up first and then go for a visit. Eye rolls.

[carusso]

Please share your observations, after you visit there.

[LCJR]

Oh, that’s what you meant. I said I plan on it on my next free day. Right now I’m working almost every day and when I’m off I have family obligations. I’ll make my way to their office when I can.

LCJR

[learningcurve2020]

But you said you were driving to their office. Oh well.

[LCJR]

I’m loaded and holding. We’re supposed to be getting some news before end of quarter. I can sit and wait on this one.


LCJR

[learningcurve2020]

What'd your car run out of power?

[LCJR]

I’m sure they’re in some type of quiet period before the merger completion.

LCJR

[learningcurve2020]

Guess that answers that. LOL

[learningcurve2020]

This new CEO appears to have no presence at all. Has anyone seen her do a talk or anything?

[LCJR]

I’m in the Springs, which is 1 1/2 hours away from Golden. Im headed to their office on my next free day. Long drive just to see an office and say hello.

LCJR

[Chartmaster]

Have not gone there yet, perhaps this week

[learningcurve2020]

What'd you find, is there actually a functioning company?

[carusso]

Why not make an appointment and talk with the CEO as well? Isn’t the idea that we shareholders are part owners of the company?

[Chartmaster]

This looks like it's bottoming, maybe I'll go visit their office with a camera

[acraft5]

He is responding to the post with the S4 Filings for the MERGER. BACk filed them on 9/29

https://www.otcmarkets.com/stock/BACK/disclosure
https://www.otcmarkets.com/filing/html?id=16961734&guid=YJ5-knTCJg7-B3h

[learningcurve2020]

What's nice, explain it to us?

[Bodhi_Trades]

Nice

[LCJR]

I finally found it, thanks!

LCJR

[LCJR]

It’s going to be volatile until the merger closing. There’s going to be a 30:1 reverse split, so now’s the time to load all you can at these prices because after closing and RS, the share price will be well over $1. This is according to the filings.

LCJR

[Golden Cross]

It is Filed with $BACK
https://www.otcmarkets.com/stock/BACK/disclosure
https://www.otcmarkets.com/filing/html?id=16961734&guid=YJ5-knTCJg7-B3h

[learningcurve2020]

.0008...She's running backwards!

[LCJR]

It’s going to run. Folks still digesting that huge PR.

LCJR

[OzzyS85]

Why is this not higher. Are peeps asleep?

[LCJR]

Has anyone seen the S-4? I checked the Edgar and SEC filings and don’t see it. Any assistance is appreciated.


LCJR

[carusso]

Yesterday’s volume was over 120 M!

[carusso]

Why not visit them then, and ask them to get their act together and get this to a penny.

[learningcurve2020]

And, I'm unaware of one trading at .001 with billions of shares outstanding. Clean it up already!


>>I am unaware of any other proteomics company with a robust patent estate, certified and accredited laboratory, and reimbursement agreements in place with major payors like Medicare that parallels what our new combined company possesses along with the leadership to execute and build value. I look forward to the upcoming investor call to delve deeper into the tremendous opportunity before us.”

[Chartmaster]

This co is real close to where I live! I'm buying 11's here today!

[Bodhi_Trades]

100bn AS but 522M at dtc

[georgeofthebungle]

6 BILLION OS lmao

[rbb]

.0017 $THER

[cityimport]

Selling the BIG GAP on the NEWS ... :))))))))))))))))))))))))))))))))))))))))

[Bodhi_Trades]

Nice news today
Form s-4 filing
Merger with $IMAC expected to complete Q 4

https://www.globenewswire.com/news-release/2023/10/04/2754661/0/en/Theralink-Announces-Filing-of-Form-S-4-Merger-with-IMAC-Holdings-Expected-During-Q4-2023.html

[Rainer]

https://www.globenewswire.com/news-release/2023/10/04/2754661/0/en/Theralink-Announces-Filing-of-Form-S-4-Merger-with-IMAC-Holdings-Expected-During-Q4-2023.html

[learningcurve2020]

Mindless pumping.

23 May, 2023,

[Bodhi_Trades]

“Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company”

https://www.prnewswire.com/news-releases/theralink-signs-definitive-merger-agreement-to-be-acquired-by-imac-holdings-a-nasdaq-listed-company-301832039.html

[Bodhi_Trades]

.0008 could be bottom. Really thin on ask.